Alnylam Pharmaceuticals (ALNY) Slumps as Researchers Raise Red Flags
Shares of Alnylam Pharmaceuticals (Nasdaq: ALNY) slumped on Thursday. Traders say the stock's decline could relate to questions raised about treatments targeting alpha-synuclein. According to reports, drugs aimed at alpha-synuclein could be making people worse. Questions raise concerns about patients in clinical trials to lower alpha-synuclein.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharma (ALNY) Announces Initiation of ALN-AAT Phase 1/2 in Alpha-1 Liver Disease
- Speculators show global commodities rout still has legs
- Regeneron (REGN) Trading Halted; Praluent Injection PDUFA Date Today
Create E-mail Alert Related CategoriesFDA, Rumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!